Quantitative multi-gene expression profiling of primary prostate cancer

Prostate

Volumn 66, Issue 14, 2006, Pages 1521-1534

  Schmidt, Uta ^a,b   Fuessel, Susanne ^a   Koch, Rainer ^a   Baretton, Gustavo B ^a   Lohse, Andrea ^a   Tomasetti, Silke ^a   Unversucht, Susanne ^a   Froehner, Michael ^a   Wirth, Manfred P ^a   Meye, Axel ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

Expression patterns; LightCycler technology; Molecular tumor marker; Primary prostate carcinoma; Quantitative real time PCR

Indexed keywords

TUMOR MARKER;

ADULT; AGED; AIBZIP GENE; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; D GPCR GENE; EZH2 GENE; GAPDH GENE; GENE EXPRESSION PROFILING; HOUSEKEEPING GENE; HPRT GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PBGD GENE; PCA3 GENE; PDEF GENE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTEIN GENE; PSA GENE; PSCA GENE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; TBP GENE; TRPM8 GENE;

AGED; ANTIGENS, NEOPLASM; BIOPSY; CELL LINE, TUMOR; DNA-BINDING PROTEINS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC SCREENING; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION FACTORS; TREATMENT FAILURE; TRPM CATION CHANNELS; TUMOR MARKERS, BIOLOGICAL;

EID: 33749069496     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20490     Document Type: Article

References (61)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin 2005;55(1):10-30.
2. Gosselaar C, Roobol MJ, Schroder FH. Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: Aggressive or insignificant? BJU Int 2005;95(2):231-237.
3. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. Jama 1997;277(18):1445-1451.
4. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure. J Clin Oncol 2005;23(22):4975-4979.
5. Nelson PS. Predicting prostate cancer behavior using transcript profiles. J Urol 2004;172(5 Pt 2):S28-32; discussion S33.
6. Landers KA, Burger MJ, Tebay MA, Purdie DM, Scells B, Samaratunga H, Lavin MF, Gardiner RA. Use of multiple biomarkers for a molecular diagnosis of prostate cancer. Int J Cancer 2005;114(6):950-956.
7. Henshall SM, Afar DE, Miller J, Horvath LG, Quinn DI, Rasiah KK, Gish K, Willhite D, Kench JG, Gardiner-Garden M, Stricker PD, Scher HI, Grygiel JJ, Agus DB, Mack DH, Sutherland RL. Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res 2003;63(14):4196-4203.
8. Kristiansen G, Pilarsky C, Wissmann C, Kaiser S, Bruemmendorf T, Roepcke S, Dahl E, Hinzmann B, Specht T, Pervan J, Stephan C, Loening S, Dietel M, Rosenthal A. Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J Pathol 2005;205(3):359-376.
9. Luo JH, Yu YP, Cieply K, Lin F, Deflavia P, Dhir R, Finkelstein S, Michalopoulos G, Becich M. Gene expression analysis of prostate cancers. Mol Carcinog 2002;33(1):25-35.
10. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, Lander ES, Loda M, Kantoff PW, Golub TR, Sellers WR. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002;1(2):203-209.
11. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003;33(1):49-54.
12. Tricoli JV, Schoenfeldt M, Conley BA. Detection of prostate cancer and predicting progression: Current and future diagnostic markers. Clin Cancer Res 2004;10(12 Pt 1):3943-3953.
13. Klein EA. What is 'insignificant' prostate carcinoma? Cancer 2004;101(9):1923-1925.
14. Qi H, Fillion C, Labrie Y, Grenier J, Fournier A, Berger L, El-Alfy M, Labrie C. AIbZIP, a novel bZIP gene located on chromosome 1q21.3 that is highly expressed in prostate tumors and of which the expression is up-regulated by androgens in LNCaP human prostate cancer cells. Cancer Res 2002;62(3):721-733.
15. Weigle B, Fuessel S, Ebner R, Temme A, Schmitz M, Schwind S, Kiessling A, Rieger MA, Meye A, Bachmann M, Wirth MP, Rieber EP. D-GPCR: A novel putative G protein-coupled receptor overexpressed in prostate cancer and prostate. Biochem Biophys Res Commun 2004;322(1):239-249.
16. Xia C, Ma W, Wang F, Hua S, Liu M. Identification of a prostate-specific G-protein coupled receptor in prostate cancer. Oncogene 2001;20(41):5903-5907.
17. Yuan TT, Toy P, McClary JA, Lin RJ, Miyamoto NG, Kretschmer PJ. Cloning and genetic characterization of an evolutionarily conserved human olfactory receptor that is differentially expressed across species. Gene 2001;278(1-2):41-51.
18. Xu LL, Stackhouse BG, Florence K, Zhang W, Shanmugam N, Sesterhenn IA, Zou Z, Srikantan V, Augustus M, Roschke V, Carter K, McLeod DG, Moul JW, Soppett D, Srivastava S. PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer. Cancer Res 2000;60(23):6568-6572.
19. Liebmann C. G protein-coupled receptors and their signaling pathways: Classical therapeutical targets susceptible to novel therapeutic concepts. Curr Pharm Des 2004;10(16):1937-1958.
20. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419(6907):624-629.
21. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. Embo J 2003;22(20):5323-5335.
22. Sellers WR, Loda M. The EZH2 polycomb transcriptional repressor-A marker or mover of metastatic prostate cancer? Cancer Cell 2002;2(5):349-350.
23. Tonini T, Bagella L, D'Andrilli G, Claudio PP, Giordano A. Ezh2 reduces the ability of HDAC1-dependent pRb2/p130 transcriptional repression of cyclin A. Oncogene 2004;23(28):4930-4937.
24. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, Debruyne FM, Ru N, Isaacs WB. DD3: A new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999;59(23):5975-5979.
25. de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, Swinkels DW, Schalken JA. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002;62(9):2695-2698.
26. Schalken JA, Hessels D, Verhaegh G. New targets for therapy in prostate cancer: Differential display code 3 (DD3(PCA3)) a highly prostate cancer-specific gene. Urology 2003;62(5 Suppl 1):34-43.
27. Oettgen P, Finger E, Sun Z, Akbarali Y, Thamrongsak U, Boltax J, Grall F, Dube A, Weiss A, Brown L, Quinn G, Kas K, Endress G, Kunsch C, Libermann TA. PDEF, a novel prostate epithelium-specific ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression. J Biol Chem 2000;275(2):1216-1225.
28. Chen H, Nandi AK, Li X, Bieberich CJ. NKX-3.1 interacts with prostate-derived Ets factor and regulates the activity of the PSA promoter. Cancer Res 2002;62(2):338-340.
29. Feldman RJ, Sementchenko VI, Gayed M, Fraig MM, Watson DK. Pdef expression in human breast cancer is correlated with invasive potential and altered gene expression. Cancer Res 2003;63(15):4626-4631.
30. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: A decade of discovery - What we have learned and where we are going. J Urol 1999;162(2):293-306.
31. Gelmini S, Tricarico C, Petrone L, Forti G, Amorosi A, Dedola GL, Serio M, Pazzagli M, Orlando C. Real-time RT-PCR for the measurement of prostate-specific antigen mRNA expression in benign hyperplasia and adenocarcinoma of prostate. Clin Chem Lab Med 2003;41(3):261-265.
32. Fuessel S, Sickert D, Meye A, Klenk U, Schmidt U, Schmitz M, Rost AK, Weigle B, Kiessling A, Wirth MP. Multiple tumor marker analyses (PSA, hK2, PSCA, trp-p8) in primary prostate cancers using quantitative RT-PCR. Int J Oncol 2003;23(1):221-228.
33. Reiter RE, Sato I, Thomas G, Qian J, Gu Z, Watabe T, Loda M, Jenkins RB. Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer. Genes Chromosomes Cancer 2000;27(1):95-103.
34. Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM, Loda M, Witte ON. Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 1998;95(4):1735-1740.
35. Sato K, Qian J, Slezak JM, Lieber MM, Bostwick DG, Bergstralh EJ, Jenkins RB. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J Natl Cancer Inst 1999;91(18):1574-1580.
36. Gu Y, Kim KH, Ko D, Nakamura K, Yasunaga Y, Moul JW, Srivastava S, Arnstein P, Rhim JS. A telomerase-immortalized primary human prostate cancer clonal cell line with neoplastic phenotypes. Int J Oncol 2004;25(4):1057-1064.
37. Zhigang Z, Wenlv S. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: Implications for prostate carcinogenesis and progression of prostate cancer. Jpn J Clin Oncol 2004;34(7):414-419.
38. Han KR, Seligson DB, Liu X, Horvath S, Shintaku PI, Thomas GV, Said JW, Reiter RE. Prostate stem cell antigen expression is associated with gleason score, seminal vesicle invasion and capsular invasion in prostate cancer. J Urol 2004;171(3):1117-1121.
39. Lam JS, Yamashiro J, Shintaku IP, Vessella RL, Jenkins RB, Horvath S, Said JW, Reiter RE. Prostate stem cell antigen is overexpressed in prostate cancer metastases. Clin Cancer Res 2005;11(7):2591-2596.
40. Xu J, Kalos M, Stolk JA, Zasloff EJ, Zhang X, Houghton RL, Filho AM, Nolasco M, Badaro R, Reed SG. Identification and characterization of prostein, a novel prostate-specific protein. Cancer Res 2001;61(4):1563-1568.
41. Edwards S, Campbell C, Flohr P, Shipley J, Giddings I, Te-Poele R, Dodson A, Foster C, Clark J, Jhavar S, Kovacs G, Cooper CS. Expression analysis onto microarrays of randomly selected cDNA clones highlights HOXB13 as a marker of human prostate cancer. Br J Cancer 2005;92(2):376-381.
42. Tsavaler L, Shapero MH, Morkowski S, Laus R. Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins. Cancer Res 2001;61(9):3760-3769.
43. Kalos M, Askaa J, Hylander BL, Repasky EA, Cai F, Vedvick T, Reed SG, Wright GL Jr, Fanger GR. Prostein expression is highly restricted to normal and malignant prostate tissues. Prostate 2004;60(3):246-256.
44. Clapham DE. TRP channels as cellular sensors. Nature 2003;426(6966):517- 524.
45. 2+ channel required for the survival of prostate cancer cells. Cancer Res 2004;64(22):8365-8373.
46. Kohler T, Rost AK, Remke H. Calibration and storage of DNA competitors used for contamination-protected competitive PCR. Biotechniques 1997;23(4):722-726.
47. De Long R, DeLong D, Clarke-Pearson D. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 1988;44:837-845.
48. Hosmer DW, Lemeshow S. Applied logistic regression. New York: Wiley; 1989.
49. Akaike H. Statistical predictor identification. Ann Inst Stat Math 1970;22:203-217.
50. de Kok JB, Ruers TJ, van Muijen GN, van Bokhoven A, Willems HL, Swinkels DW. Real-time quantification of human telomerase reverse transcriptase mRNA in tumors and healthy tissues. Clin Chem 2000;46(3):313-318.
51. de Kok JB, Roelofs RW, Giesendorf BA, Pennings JL, Waas ET, Feuth T, Swinkels DW, Span PN. Normalization of gene expression measurements in tumor tissues: Comparison of 13 endogenous control genes. Lab Invest 2005;85(1):154-159.
52. Veltri RW, Khan MA, Miller MC, Epstein JI, Mangold LA, Walsh PC, Partin AW. Ability to predict metastasis based on pathology findings and alterations in nuclear structure of normal-appearing and cancer peripheral zone epithelium in the prostate. Clin Cancer Res 2004;10(10):3465-3473.
53. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005;115(6):1503-1521.
54. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 2004;113(6):913-923.
55. Latil A, Bieche I, Chene L, Laurendeau I, Berthon P, Cussenot O, Vidaud M. Gene expression profiling in clinically localized prostate cancer: A four-gene expression model predicts clinical behavior. Clin Cancer Res 2003;9(15):5477-5485.
56. Fromont G, Chene L, Vidaud M, Vallancien G, Mangin P, Fournier G, Validire P, Latil A, Cussenot O. Differential expression of 37 selected genes in hormone-refractory prostate cancer using quantitative taqman real-time RT-PCR. Int J Cancer 2005;114(2):174-181.
57. Burger MJ, Tebay MA, Keith PA, Samaratunga HM, Clements J, Lavin MF, Gardiner RA. Expression analysis of delta-catenin and prostate-specific membrane antigen: Their potential as diagnostic markers for prostate cancer. Int J Cancer 2002;100(2):228-237.
58. Gjengsto P, Paus E, Halvorsen OJ, Eide J, Akslen LA, Wentzel-Larsen T, Hoisaeter PA. Predictors of prostate cancer evaluated by receiver operating characteristics partial area index: A prospective institutional study. J Urol 2005;173(2): 425-428.
59. Nam RK, Zhang WW, Jewett MA, Trachtenberg J, Klotz LH, Emami M, Sugar L, Sweet J, Toi A, Narod SA. The use of genetic markers to determine risk for prostate cancer at prostate biopsy. Clin Cancer Res 2005;11(23):8391-8397.
60. Konishi N, Nakamura M, Ishida E, Shimada K, Mitsui E, Yoshikawa R, Yamamoto H, Tsujikawa K. High expression of a new marker PCA-1 in human prostate carcinoma. Clin Cancer Res 2005;11(14):5090-5097.
61. Schalken JA. Validation of molecular targets in prostate cancer. BJU Int 2005;96(Suppl 2):23-29.